Compare · A vs CTKB
A vs CTKB
Side-by-side comparison of Agilent Technologies Inc. (A) and Cytek Biosciences Inc. (CTKB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and CTKB operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $37.13B, about 62.2x CTKB ($596.6M).
- Over the past year, A is up 15.3% and CTKB is up 47.8% - CTKB leads by 32.5 points.
- A has been more active in the news (9 items in the past 4 weeks vs 4 for CTKB).
- A has more recent analyst coverage (25 ratings vs 13 for CTKB).
- Company
- Agilent Technologies Inc.
- Cytek Biosciences Inc.
- Price
- $131.43-3.42%
- $4.63-0.32%
- Market cap
- $37.13B
- $596.6M
- 1M return
- +2.39%
- +13.60%
- 1Y return
- +15.31%
- +47.85%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- 2021
- News (4w)
- 9
- 4
- Recent ratings
- 25
- 13
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Latest A
- Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
- Jefferies resumed coverage on Agilent with a new price target
- Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
- Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
- Senior Vice President Kirkwood Jonah Prevost covered exercise/tax liability with 30 shares, decreasing direct ownership by 0.21% to 14,108 units (SEC Form 4)
- Bernstein resumed coverage on Agilent with a new price target
- Agilent Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Excellere Partners and GHO Capital complete sale of Biocare Medical to Agilent Technologies
- Agilent Completes Acquisition of Biocare Medical
- Piper Sandler initiated coverage on Agilent with a new price target
Latest CTKB
- Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
- SEC Form 8-K filed by Cytek Biosciences Inc.
- SEC Form 3 filed by new insider Feuchtwang Ilan
- SEC Form 8-K filed by Cytek Biosciences Inc.
- CHIEF TECHNOLOGY OFFICER Yan Ming gifted 135,892 shares, decreasing direct ownership by 3% to 4,796,688 units (SEC Form 4)
- SEC Form 8-K filed by Cytek Biosciences Inc.
- Director Ball Jack converted options into 43,973 shares, increasing direct ownership by 103% to 86,678 units (SEC Form 4)
- SEC Form 4 filed by Director Muir Glenn P
- SEC Form 3 filed by new insider Muir Glenn P
- SEC Form 4 filed by Director Chin Richard